ALDX Aldeyra Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALDX

Price (delayed)

$4.15

Market cap

$246.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$159.74M

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's ...

Highlights
The net income has soared by 51% YoY and by 20% from the previous quarter
The company's EPS has surged by 51% YoY and by 20% QoQ
The quick ratio is down by 40% year-on-year and by 4.4% since the previous quarter
ALDX's equity is down by 17% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aldeyra.com
Peers: REGN

Key stats

What are the main financial stats of ALDX
Market
Shares outstanding
59.41M
Market cap
$246.57M
Enterprise value
$159.74M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$27.93M
EBITDA
-$27.67M
Free cash flow
-$30.85M
Per share
EPS
-$0.51
Free cash flow per share
-$0.52
Book value per share
$1.93
Revenue per share
$0
TBVPS
$2.38
Balance sheet
Total assets
$141.3M
Total liabilities
$27.88M
Debt
$15.66M
Equity
$113.42M
Working capital
$119.17M
Liquidity
Debt to equity
0.14
Current ratio
6.5
Quick ratio
6.14
Net debt/EBITDA
3.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-20.3%
Return on equity
-24.7%
Return on invested capital
-322%
Return on capital employed
-23.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALDX stock price

How has the Aldeyra Therapeutics stock price performed over time
Intraday
1.47%
1 week
8.64%
1 month
27.69%
1 year
-47.73%
YTD
18.23%
QTD
25.38%

Financial performance

How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.38M
Net income
-$30.01M
Gross margin
N/A
Net margin
N/A
The net income has soared by 51% YoY and by 20% from the previous quarter
Aldeyra Therapeutics's operating income has increased by 44% YoY and by 17% QoQ

Growth

What is Aldeyra Therapeutics's growth rate over time

Valuation

What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
2.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 51% YoY and by 20% QoQ
ALDX's price to book (P/B) is 21% less than its 5-year quarterly average of 2.7 and 18% less than its last 4 quarters average of 2.6
ALDX's equity is down by 17% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Aldeyra Therapeutics business performance
The return on invested capital has dropped by 136% year-on-year but it has surged by 88% since the previous quarter
The return on assets has increased by 38% year-on-year and by 16% since the previous quarter
The ROE has grown by 37% YoY and by 16% from the previous quarter

Dividends

What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALDX.

Financial health

How did Aldeyra Therapeutics financials performed over time
The quick ratio is down by 40% year-on-year and by 4.4% since the previous quarter
The current ratio has declined by 38% year-on-year and by 2.1% since the previous quarter
Aldeyra Therapeutics's debt is 86% lower than its equity
The company's debt to equity rose by 17% YoY and by 8% QoQ
ALDX's equity is down by 17% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.